Overview
- Emily Henders, 37, received an autologous CAR T-cell infusion at University College London Hospital in October and reported feeling well afterward.
- The therapy modifies the patient’s T cells to target and eliminate disease-driving B cells thought to underlie MS relapses and progression.
- Investigators are evaluating obe-cel, a UCL-developed CAR T licensed to Autolus, which is approved for certain leukemias but remains experimental for MS.
- The early-stage trial prioritizes safety and biological effects, plans to enroll up to 18 participants internationally, and is targeting completion of recruitment by early 2027.
- Clinicians hope a single treatment could induce prolonged remission and reduce reliance on ongoing drugs, a goal with significant implications for more than 150,000 people living with MS in the UK.